MOXICIP Eye Ointment (Moxifloxacin 0.5%)
|
|
- Michael Welch
- 5 years ago
- Views:
Transcription
1 Published on: 19 Sep 2014 MOXICIP Eye Ointment (Moxifloxacin 0.5%) Composition Moxifloxacin 0.5% (5 mg/ml) Dosage Form Ophthalmic Ointment Pharmacology Pharmacodynamics Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs. Moxifloxacin is an 8-methoxy fluoroquinolone with a diazabicyclononyl ring at the C7 position. The antibacterial action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action for quinolones, including moxifloxacin, is different from that of macrolides, aminoglycosides, or tetracyclines. Therefore, moxifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to moxifloxacin. There is no cross-resistance between moxifloxacin and the aforementioned classes of antibiotics. Cross resistance has been observed between systemic moxifloxacin and some other quinolones. Mechanisms of Resistance: Resistance to fluoroquinolones, including moxifloxacin, occurs generally by chromosomal mutations in genes encoding DNA gyrase and topoisomerase IV. In Gram-negative bacteria, moxifloxacin resistance can be due to mutations in mar (multiple antibiotic resistance) and the qnr (quinolone resistance) gene systems. Resistance is also associated with expression of bacteria efflux proteins and inactivating enzymes. Cross-resistance with beta-lactams, macrolides and aminoglycosides is not expected due to differences in mode of action. In vitro resistance to moxifloxacin develops via multiple-step mutations. Resistance to moxifloxacin occurs in vitro at a general frequency of between to < for Gram-positive bacteria. Susceptibility testing breakpoints There are no pharmacological data correlated with clinical outcome for moxifloxacin administered as a topical agent. As a result, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) suggests the following epidemiological cut-off values (ECOFF mg/l) derived from MIC distribution curves to indicate susceptibility to topical moxifloxacin. Corynebacterium Staphylococcus aureus ND
2 Staphylococcus, coag-neg. Streptococcus pneumoniae Streptococcus pyogenes Streptococcus, viridans group Enterobacter spp. Haemophilus influenzae Klebsiella spp. Moraxella catarrhalis Morganella morganii Neisseria gonorrhoeae Pseudomonas aeruginosa Serratia marcescens 0.5 mg/l 0.5 mg/l 0.5 mg/l mg/l mg/l 4 mg/l 1 mg/l The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of moxifloxacin in at least some types of infections is questionable. Moxifloxacin has been shown to be active against most strains of the following microorganisms: Aerobic Gram-positive microorganisms Corynebacterium species 1 including Corynebacterium diphtheriae Micrococcus luteus 1 Staphylococcus aureus (methicillin susceptible) Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri 1 Streptococcus pyogenes Streptococcus pneumoniae Streptococcus viridans group Aerobic Gram-negative microorganisms Acinetobacter lwoffii 1 Haemophilus influenzae Haemophilus parainfluenzae 1 Enterobacter cloacae Klebsiella oxytoca Moraxella catarrhalis Serratia marcescens Anaerobic micro-organisms Propionibacterium acnes Other microorganisms
3 Chlamydia trachomatis 1 Efficacy for this organism was studied in fewer than 10 infections. Species for which acquired resistance may be a problem Aerobic Gram-positive microorganisms: Staphylococcus aureus (methicillin resistant) Staphylococcus, coagulase-negative species (methicillin resistant) Aerobic Gram-negative microorganisms: Neisseria gonorrhoeae Other microorganisms: None Inherently resistant organisms Aerobic Gram-negative microorganisms: Pseudomonas aeruginosa Other microorganisms: None The following in vitro data are also available, but their clinical significance in ophthalmic infections is unknown. The safety and effectiveness of moxifloxacin in treating ophthalmological infections due to these microorganisms have not been established in adequate and well-controlled trials. The following organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the in vitro systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival infections. Moxifloxacin exhibits in vitro minimal inhibitory concentrations (MICs) of 2 microgram/ml or less (systemic susceptible breakpoint) against most ( 90%) strains of the following ocular pathogens. Aerobic Gram-positive microorganisms Listeria monocytogenes Staphylococcus saprophyticus Streptococcus agalactiae Streptococcus mitis Streptococcus pyogenes Streptococcus Group C, G and F Aerobic Gram-negative microorganisms Acinetobacter baumannii Acinetobacter calcoaceticus Citrobacter freundii Citrobacter koseri Enterobacter aerogenes Enterobacter cloacae Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Moraxella catarrhalis Morganella morganii Neisseria gonorrhoeae Proteus mirabilis
4 Proteus vulgaris Pseudomonas stutzeri Anaerobic microorganisms Clostridium perfringens Fusobacterium species Prevotella species Propionibacterium acnes Other microorganisms Chlamydia pneumoniae Legionella pneumophila Mycobacterium avium Mycobacterium marinum Mycoplasma pneumoniae Pharmacokinetics Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of moxifloxacin three times a day. The mean steady-state C max (2.7 ng/ml) and estimated daily exposure AUC (45 ng hr/ml) values were 1,600 and 1,000 times lower than the mean C max and AUC reported after therapeutic 400 mg oral doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours. Indications Moxifloxacin ophthalmic ointment is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-positive Microorganisms Corynebacterium species 2 Micrococcus luteus 2 Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri 2 Streptococcus pneumoniae Streptococcus viridans group Aerobic Gram-negative Microorganisms Acinetobacter lwoffii 2 Haemophilus influenzae Haemophilus parainfluenzae 2 Other Microorganisms Chlamydia trachomatis 2 Efficacy for this organism was studied in fewer than 10 infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
5 Dosage And Administration The recommended dosage regimen for the treatment of bacterial conjunctivitis is: Apply half-inch ribbon three times a day on the first two days. For the next five days apply half-inch ribbon two times a day. Contraindications Moxifloxacin ophthalmic ointment is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication. Warnings And Precautions General In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated. As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining. Tendon inflammation and rupture may occur with systemic fluoroquinolone therapy including moxifloxacin, particularly in older patients and those treated concurrently with corticosteroids. Following ophthalmic administration of moxifloxacin ophthalmic solution, plasma concentrations of moxifloxacin are much lower than after therapeutic oral doses of moxifloxacin, however, caution should be exercised and treatment with moxifloxacin ophthalmic solution should be discontinued at the first sign of tendon inflammation. Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis. Moxifloxacin should not be used for the prophylaxis or empiric treatment of gonococcal conjunctivitis, including gonococcal ophthalmia neonatorum, because of the prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae. Patients with eye infections caused by Neisseria gonorrhoeae should receive appropriate systemic treatment. Data are very limited to establish efficacy and safety of moxifloxacin in the treatment of conjunctivitis in neonates. Therefore, use of this medicinal product to treat conjunctivitis in neonates is not recommended. Neonates with ophthalmia neonatorum should receive appropriate treatment for their condition, e.g. systemic treatment in cases caused by Chlamydia trachomitis or Neisseria gonorrhoeae. The medicinal product is not recommended for the treatment of Chlamydia trachomatis in patients less than 2 years of age as it has not been evaluated in such patients. Patients older than 2 years of age with eye infections caused by Chlamydia trachomitis should receive appropriate systemic treatment. Drug Interactions Drug-drug interaction studies have not been conducted with MOXICIP ophthalmic ointment. In vitro studies indicate that
6 moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by this cytochrome P450 isozymes. Given the low systemic concentration of moxifloxacin following topical ocular administration of the medicinal product, drug interactions are unlikely to occur. Pregnancy Pregnancy Category C Since there are no adequate and well-controlled studies in pregnant women, moxifloxacin ophthalmic ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation Moxifloxacin has not been measured in human milk, although it can be presumed to be excreted in human milk. Caution should be exercised when moxifloxacin ophthalmic ointment is administered to a lactating female. Paediatric Use The safety and effectiveness of moxifloxacin in infants below 1 year of age have not been established. There is no evidence that the ophthalmic administration of moxifloxacin has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals. Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients. Effects on Ability to Drive and Use Machines Moxifloxacin has no or negligible influence on the ability to drive and use machines, however, as with any eye drops, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient should wait until their vision clears before driving or using machinery. Undesirable Effects Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1-6% of patients. Non-ocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis. In clinical studies involving 2,252 patients, moxifloxacin ophthalmic solution was administered up to 8 times a day, with 1,900 of these patients receiving treatment 3 times daily. The overall safety population that received the medicinal product consisted of 1,389 patients from the United States and Canada, 586 patients from Japan and 277 patients from India. No serious ophthalmic or systemic undesirable effects related to the medicinal product were reported in any of the clinical studies. The most frequently reported treatment-related undesirable effects with the medicinal product were eye irritation and eye pain, occurring at an overall incidence of 1 to 2%. These reactions were mild in 96% of those patients who experienced them, with only 1 patient discontinuing therapy as a result. The following undesirable effects were assessed to be treatment-related and are classified according to the following convention: very common ( 1/10), common ( 1/100 to <1/10), uncommon ( 1/1,000 to <1/100), rare ( 1/10,000 to
7 <1/1000), or very rare (<1/10,000) or not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in decreasing order of seriousness. Table 1: Undesirable effects System Organ Classification Blood and lymphatic system Immune system Nervous system Eye Frequency Uncommon Common Uncommon Adverse reactions haemoglobin decreased hypersensitivity headache paresthesia dizziness eye pain, eye irritation punctate keratitis, dry eye, conjunctival haemorrhage, ocular hyperaemia, eye pruritus, eyelid oedema, ocular discomfort, corneal epithelium defect, corneal disorder, conjunctivitis, blepharitis, eye swelling, conjunctival oedema, vision blurred, visual acuity reduced, asthenopia, erythema of eyelid endophthalmitis, ulcerative keratitis, corneal erosion, corneal abrasion, intraocular pressure increased, corneal opacity, corneal infiltrates, corneal deposits, eye allergy, keratitis, corneal oedema, photophobia, eyelid oedema, lacrimation increased, eye discharge, foreign body sensation in eyes Cardiac palpitations Respiratory, thoracic and mediastinal Gastrointestional Hepatobiliary Skin and subcutaneous tissue Uncommon nasal discomfort, pharyngolaryngeal pain, sensation of foreign body (throat) dyspnoea dysgeusia vomiting nausea alanine aminotransferase increased, gammaglutamyltransferase increased erythema, rash, pruritus, urticaria Ruptures of the shoulder, hand, Achilles, or other tendons that required surgical repair or resulted in prolonged disability have been reported in patients receiving systemic fluoroquinolones. Studies and post marketing experience with systemic quinolones indicate that a risk of these ruptures may be increased in patients receiving corticosteroids, especially geriatric patients and in tendons under high stress, including Achilles tendon.
8 Paediatric Population In clinical trials, topical moxifloxacin 0.5% has shown to be safe in paediatric patients, including neonates. In patients under 18 years old, the two most frequent adverse reactions were eye irritation and eye pain, both occurring at an incidence rate of 0.9%. Based on data from clinical trials involving paediatric patients, including neonates, the type and severity of adverse reactions in the paediatric population are similar to those in adults. If you experience any side-effects, talk to your doctor or pharmacist or write to You can also report side effects directly via the national pharmacovigilance program of India by calling on By reporting side-effects, you can help provide more information on the safety of this product. Overdosage The limited holding capacity of the conjunctival sac for ophthalmic products practically precludes any overdosing of the medicinal product. The total amount of moxifloxacin in a single container is too small to induce adverse effects after accidental ingestion. Incompatibility Not applicable Shelf-Life 24 months Storage And Handling Instructions Store in a cool place Packaging Information MOXICIP Eye Ointment: Tube of 5gm Information For Patients Avoid contaminating the applicator tip with material from the eye, fingers or other source. Systemically administered quinolones including moxifloxacin have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction. Last Updated: November 2018 Last Reviewed: November 2018 MOXICIP Eye Ointment Source URL:
Moxifloxacin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as:
BASILOX 0.5% Composition Moxifloxacin 0.5% (5 mg/ml) Eye Drops Action BASILOX 0.5 Eye Drops contains the fourth-generation fluoroquinolone, Moxifloxacin. Moxifloxacin has in vitro activity against a wide
More informationOther ingredients are sodium chloride and purified water.
Page 1 of 7 SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM EXOCIN (Eye Drops) COMPOSITION EXOCIN contains: Preservative: Benzalkonium chloride 0,005 % m/v Other ingredients are sodium chloride
More informationPage 1 of 9. Moxifloxacin Ophthalmic Solution USP, 0.5% Sterile topical ophthalmic solution Initial U.S. Approval: 1999
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Moxifloxacin Ophthalmic Solution USP safely and effectively. See full prescribing information for
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN SKIN / ANTIBIOTIC OINTMENT
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN SKIN / ANTIBIOTIC OINTMENT Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ointment / Ophthalmic Ointment
More informationThe active component of CHLOROMYCETIN eye ointment is chloramphenicol.
PRODUCT INFORMATION CHLOROMYCETIN EYE OINTMENT chloramphenicol 10 mg per g NAME OF THE MEDICINE The active component of CHLOROMYCETIN eye ointment is chloramphenicol. OHH O 2 N C - C - CH 2 OH H NHCOCHC
More information4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases
4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cephacare flavour 50 mg tablets for cats and dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME CIPROFLOXACIN (Teva), 0.3% w/v, Eye Drops NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains ciprofloxacin hydrochloride 3.5 mg equivalent to ciprofloxacin
More informationB. PACKAGE LEAFLET 1
B. PACKAGE LEAFLET 1 PACKAGE LEAFLET NICILAN 400 mg/100 mg tablets for dogs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Marbotab P 20 mg tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbotab P 20 mg tablets for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrocare 50 mg/ml Solution for Injection for Cattle, Pigs, Dogs and Cats (UK, IE, FR) Floxadil 50 mg/ml Solution for Injection
More informationGENTAMICIN SULFATE- gentamicin sulfate solution/ drops Pacific Pharma, Inc GENTAMICIN SULFATE ophthalmic s olution, USP 0.
GENTAMICIN SULFATE- gentamicin sulfate solution/ drops Pacific Pharma, Inc. ---------- GENTAMICIN SULFATE ophthalmic s olution, USP 0.3% sterile DESCRIPTION Gentamicin sulfate ophthalmic solution, USP
More information1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and
More informationPackage leaflet: Information for the user. GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin
Package leaflet: Information for the user GENTAMICIN VISION 3 mg/ml eye drops, solution Gentamicin Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Boflox flavour 20 mg tablets for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare flavour 80mg tablets for dogs (UK and IE) Marbocare F 80mg tablets for dogs (FR) Odimar 80mg tablets for dogs (BE,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbocare 20 mg/ml solution for injection for cattle and pigs (UK, IE, FR) Odimar 20 mg/ml solution for injection for cattle
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. GENTAMICIN VISION 3 mg/g eye ointment Gentamicin
PACKAGE LEAFLET: INFORMATION FOR THE USER GENTAMICIN VISION 3 mg/g eye ointment Gentamicin Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to
More informationTable 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.
Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Cefaseptin 750 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains: Active substance: cefalexin
More informationDOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO. OTIPRIO (ciprofloxacin
More informationSUMMARY OF PRODUCT CHARACTERISTICS
[Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS (Based on the current SPC of the reference product Baytril RSI 100 mg/ml Injektionslösung für Rinder und Schweine) 1 1. NAME OF THE VETERINARY
More informationPRODUCT MONOGRAPH. Pr CILOXAN 0.3% Ciprofloxacin Hydrochloride Ophthalmic Solution and Ointment (0.3% as ciprofloxacin) Antibacterial Agent
PRODUCT MONOGRAPH Pr CILOXAN 0.3% Ciprofloxacin Hydrochloride Ophthalmic Solution and Ointment (0.3% as ciprofloxacin) Antibacterial Agent ALCON CANADA INC. Date of Preparation 2665 Meadowpine Blvd. March
More informationMARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL 10%, solution for injection for cattle and swine 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marbofloxacin...100.0
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More information[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Pneumospectin 50 mg/ml +100 mg/ml solution for injection for cattle (calves), sheep, goat, pig,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amfipen LA 100 mg/ml suspension for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Each ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ENROXIL 100 mg/ml solution for injection for cattle and pigs (AT, IE, NL, UK) ENROXAL 100 mg/ml solution for injection for
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Kelacyl 100 mg/ml, solution for injection for cattle and pigs (BG, CY, CZ, DE, EL, FR, HU, IE, IT, LT, PL, PT, RO, SK, UK)
More informationPRESCRIBING INFORMATION
PRESCRIBING INFORMATION Pr PENTAMYCETIN Chloramphenicol Ophthalmic Solution USP 0.25%, 0.5% Chloramphenicol Ophthalmic Ointment USP 1% Antibiotic Pr PENTAMYCETIN/HC Chloramphenicol and Hydrocortisone Eye
More informationTherios 300 mg and 750 mg Palatable Tablets for Dogs
Ceva Animal Health Ltd Telephone: 01494 781510 Website: www.ceva.com Email: cevauk@ceva.com Therios 300 mg and 750 mg Palatable Tablets for Dogs Species: Therapeutic indication: Active ingredient: Product:
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Genta 50 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substances Gentamicin sulphate equivalent to Gentamicin
More informationC&W Three-Year Cumulative Antibiogram January 2013 December 2015
C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations...
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystatin Orifarm, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients with known effect: - Methyl parahydroxybenzoate
More informationEar drops suspension. A smooth, uniform, white to off-white viscous suspension.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT OTOMAX EAR DROPS SUSPENSION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of the veterinary medicinal product contains:
More informationEmpirical formula: C17H18FN303.HCl.H20
PRODUCT INFORMATION CILOXAN * (ciprofloxacin) 0.3% Ear Drops NAME OF THE MEDICINE CILOXAN Ear Drops contain ciprofloxacin hydrochloride (equivalent to 3 mg/ml ciprofloxacin base). The chemical structure
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More information4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals
1.B1. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AMOXYCOL Soluble Powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substances: Amoxicillin trihydrate 640.0
More informationSummary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs
Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotab 50 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance Enrofloxacin
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystimex, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients: Methyl parahydroxybenzoate 1 mg Sodium
More informationFor the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:
SUMMARY OF PRODUCT CHARCTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Amoxycare Suspension for Injection 15% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active Substance(s)
More informationPart II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)
Clindacyl 25mg Tablets Vm 08007/4104 Part II SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLINDACYL 25 MG TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. Ciprofloxacin Ophthalmic Solution, USP 0.3% w/v (as ciprofloxacin hydrochloride)
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr CILOXAN Ciprofloxacin Ophthalmic Solution, USP 0.3% w/v (as ciprofloxacin hydrochloride) Antibacterial Agent and Pr CILOXAN Ciprofloxacin Ophthalmic
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationAMOCLAN HIKMA PHARMACEUTICALS
09-15 AMOCLAN HIKMA PHARMACEUTICALS (Amoxycillin and Clavulanic acid) ACTION Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS
1.B. SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Lamox 800 mg/g powder for use in drinking water for chickens and pigs 2. QUALITATIVE
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cefenil 50 mg/ml Powder and Solvent for Solution for Injection for and. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Powder vial
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Card box and package leaflet for brown glass bottle (Type 1) 1. NAME OF THE
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEFLEX safely and effectively. See full prescribing information for KEFLEX KEFLEX (cephalexin) capsules,
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Streptacare Suspension for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: Each ml contains: Procaine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Quiflor 20 mg/ml solution for injection for cattle, pigs and dogs [AT, BE, DK, DE, EL, ES IT, NL, PT, UK] Quiflox 20 mg/ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fluclon 250 mg Capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250mg of flucloxacillin as flucloxacillin sodium.
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Amphen 200 mg/g Granules for use in drinking water for pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each g contains: Active
More informationCleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria
Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria This document has been developed in accordance with current applicable infection
More informationCleaning and Disinfection Protocol Vegetative Bacteria
Cleaning and Disinfection Protocol Vegetative Bacteria This document has been developed in accordance with current applicable infection control and biosecurity guidelines. It is intended for use as a guideline
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SANDOZ CIPROFLOXACIN
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SANDOZ CIPROFLOXACIN Ciprofloxacin Hydrochloride Ophthalmic Solution (0.3% as ciprofloxacin) Antibacterial Agent Sandoz Canada Inc. 145 Jules-Léger
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Metrobactin 500 mg tablets for dogs and cats (AT, BE, BG, CY, CZ, DE, EL, ES, FR, HR, HU, IE, IT, LU, NL, PL, PT, RO, SI,
More informationPackage leaflet: Information for the user. HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol
Package leaflet: Information for the user HYDROCORTISON CUM CHLORAMPHENICOL 5 mg/g + 2 mg/g eye ointment hydrocortisone acetate, chloramphenicol Read all of this leaflet carefully before you start using
More informationPRODUCT MONOGRAPH OPHTHALMIC SOLUTION. Contains: Trimethoprim 0.1 % & Polymyxin B units/ml. Antibacterial Agent
PRODUCT MONOGRAPH Pr SANDOZ POLYTRIMETHOPRIM OPHTHALMIC SOLUTION Contains: Trimethoprim 0.1 % & Polymyxin B 10 000 units/ml Antibacterial Agent Sandoz Canada Inc. 145 Jules-Leger Boucherville (QC) J4B
More informationStudy Type of PCR Primers Identified microorganisms
Study Type of PCR Primers Identified microorganisms Portillo et al, Marín et al, Jacovides et al, Real-time multiplex PCR (SeptiFasta, Roche Diagnostics) 16S rr gene was amplified using conventional PCR.
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995, as amended European Communities (Animal Remedies) (No. 2) Regulations 2007 VPA: 10999/033/001A Case No: 7006569 The in exercise of the powers conferred on it by Animal Remedies
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationIrish Medicines Board
IRISH MEDICINES BOARD ACT 1995 EUROPEAN COMMUNITIES (ANIMAL REMEDIES) (No. 2) REGULATIONS 2007 (S.I. No. 786 of 2007) VPA: 10999/056/001 Case No: 7004318 The Irish Medicines Board in exercise of the powers
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DOXYPRIM 40% soluble powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Doxycycline hyclate 400.0 mg Excipients:
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationAPPROVED PACKAGE INSERT. Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin base.
APPROVED PACKAGE INSERT SCHEDULING STATUS: S4 PROPRIETARY NAMEAND DOSAGE FORM: DALACIN C TM 150 mg (Capsules) COMPOSITION: Each capsule contains clindamycin hydrochloride equivalent to 150 mg clindamycin
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Excipients: Contains 4% w/w cetyl alcohol and 7% w/w propylene glycol.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT FLAMAZINE Cream 1 % w/w 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Contains Silver sulfadiazine 1 % w/w Excipients: Contains 4% w/w
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Revised: May 2014 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Flavour 150 mg Tablets for dogs (United Kingdom, Austria, Belgium, Germany, Denmark, Greece, Ireland,
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One g contains:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Issued March 2017 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Recicort 1.77 mg/ml + 17.7 mg/ml ear drops, solution for dogs and cats Recicort vet 1.77 mg/ml + 17.7 mg/ml
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Linco-Sol 400 mg/g powder for use in drinking water for pigs and chickens 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tilmovet 250 mg/ml Concentrate for Oral Solution (BE, BG, CZ, EL, HU, IE, NL, PL, RO, UK) for pigs, chickens, turkeys and
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationUnshakeable confidence
NEW PRODUCT OF THE YEAR as voted by vets for the 2nd year running** Unshakeable confidence Osurnia is the only otitis externa* treatment that applies like a liquid and stays like a gel. Right where you
More informationTopical Antibiotic Update. Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures
Topical Antibiotic Update Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures What do we have? We currently have many highly effective
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Carofertin 10 mg/ml Emulsion for injection for cattle and pigs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active
More information